According to new data from a Michigan Medicine-led trial, the first and only approved gene therapy for adults with bleeding disorder hemophilia B remained safe and effective two years after treatment. Steven Pipe, M.D., professor of pediatrics and pathology at the U-M Medical School Hospital, discusses this transformative and clinical trial.
